Printer Friendly
The Free Library
19,573,952 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

CEO INTERVIEW: W.SCOTT HARKONEN - INTERMUNE PHARMACEUTICALS INC (ITMN).


(PAL232) W.SCOTT HARKONEN - INTERMUNE PHARMACEUTICALS INC inc - /ink/ increment, i.e. increase by one. Especially used by assembly programmers, as many assembly languages have an "inc" mnemonic.

Antonym: dec.
 (ITMN). Describes the company's business and its background; prospects for the industry, with positive and negative trends; competitive threats; strategic opportunities for the firm including its marketing plans and acquisition potential; management strength and organization; and the financial prospects of the firm looking forward. Sector: Biotechnology. Published date 6/2/02. Tickers featured: ITMN. Complete text approximately 3000 words. Document # PAL232.

CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  INTERVIEWS, The Wall Street Transcript, 67 Wall Street, NY 10005. Voice (212) 952 7433. Fax: (212) 668-9842. E-mail: transcript@twst.com.

***
COPYRIGHT 2002 Wall Street Transcript Corporation
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Comment:CEO INTERVIEW: W.SCOTT HARKONEN - INTERMUNE PHARMACEUTICALS INC (ITMN).(Brief Article)
Publication:Wall Street Transcript Digest
Article Type:Brief Article
Geographic Code:1USA
Date:Jun 10, 2002
Words:90
Previous Article:CEO INTERVIEW: STEVEN BERNITZ - ORGANOGENESIS INC (ORG).
Next Article:CEO INTERVIEW: STEPHEN SHERWIN - CELL GENESYS INC (CEGE).
Topics:



Related Articles
W. SCOTT HARKONEN - INTERMUNE PHARMACEUTICALS INC (ITMN).
INTERMUNE'S 2ND. QTR. ACTIMMUNE SALES INCREASE BY 178%.
INTERMUNE'S 2ND. QTR. ACTIMMUNE SALES INCREASE BY 178%.
INTERMUNE FILES NDS FOR ACTIMMUNE IN CANADA.
INTERMUNE INITIATES PHASE II TRIAL OF ACTIMMUNE.
INTERMUNE/BOEHRINGER TO COMMERCIALIZE INTERFERON/GAMMA-1B.
CEO INTERVIEW: W.SCOTT HARKONEN - INTERMUNE PHARMACEUTICALS INC (TMM).
CEO INTERVIEW: W.SCOTT HARKONEN - INTERMUNE PHARMACEUTICALS INC (ITMN).
InterMune and Mondobiotech form asthma collaboration.
CEO INTERVIEW: W.SCOTT HARKONEN - INTERMUNE PHARMACEUTICALS INC (ITMN).

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles